| Date | Title | Description |
| 02.09.2026 | Silence Therapeutics to Participate in Three September Investor Conferences | - |
| 15.08.2026 | Silence Therapeutics Secures $175 Million in Upsized Public Offering | Silence Therapeutics successfully completed an upsized public offering. The biotechnology firm raised $175 million. This significantly exceeded its initial $150 million target. Investors showed strong confidence in Silence's innovative siRN... |
| 14.08.2026 | Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs | - |
| 12.08.2026 | Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering | Silence Therapeutics plc (“Silence” or the “Company”) , a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has priced its previously announced underwritten publi... |
| 10.08.2026 | Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares | Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has commenced an underwritten public offering of approx... |
| 10.08.2026 | Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile | Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in... |
| 10.08.2026 | Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results | Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026.
Business Highli... |
| 09.08.2026 | Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera | Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of di... |
| 11.06.2026 | Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera | Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating div... |
| 27.05.2026 | Silence Therapeutics to Participate in Jefferies Global Healthcare Conference | Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferie... |
| 12.05.2026 | Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference | Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a... |
| 07.05.2026 | Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results | Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2026, a... |
| 05.03.2026 | Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results | Silence Therapeutics plc, Nasdaq: SLN, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided an ... |
| 15.12.2025 | Silence Therapeutics Announces Leadership Changes | Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company’s President, Chie... |
| 12.11.2025 | Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference | Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Confere... |
| 06.11.2025 | Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the third quarter ended September 30, 202... |
| 22.02.2022 | Another biotech shuffles its C-suite as Silence CEO steps down | Silence Therapeutics became the latest biotech to see its chief executive hit the exit.
Mark Rothera is leaving effective immediately, Silence announced late Monday, marking the end of his roughly 17-month tenure. In his place, the biotech ... |
| 05.01.2022 | Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference | Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference
5 January 2022
LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and deli... |
| 12.12.2021 | New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases | New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases Data presented at 2021 ASH annual meeting showed durable reductions in serum iron and transferrin saturation, strong safety profile... |
| 01.12.2021 | Silence Therapeutics Welcomes Deep Track Capital as New Shareholder | 1 December 2021
LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases w... |
| 01.12.2021 | Silence Therapeutics Welcomes Deep Track Capital as New Shareholder | 1 December 2021
LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases w... |
| 30.11.2021 | Silence Therapeutics Begins Exclusive Nasdaq Trading | Silence Therapeutics Begins Exclusive Nasdaq Trading
30 November 2021
LONDON, Silence Therapeutics plc, Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfer... |
| 26.11.2021 | Silence Therapeutics plc: Update on AIM Delisting - Form 6-K | Silence Therapeutics plc: Update on AIM Delisting
26 November 2021
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short... |
| 11.11.2021 | Silence Therapeutics to Present at Jefferies London Healthcare Conference | Silence Therapeutics to Present at Jefferies London Healthcare Conference
11 November 2021
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel... |
| 08.11.2021 | Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder | LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ('Silence' or 'the Company'), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with... |
| 05.11.2021 | Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder | Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder
5 November 2021
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel... |
| 05.11.2021 | Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder | Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder
5 November 2021
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel... |
| 01.11.2021 | Results of General Meeting - Form 6-K | Results of General Meeting
1 November 2021
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic... |
| 21.10.2021 | Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day | Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication being assessed using endogenous hepcidin mo... |
| 21.10.2021 | Silence Therapeutics : Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day | Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication being assessed using endogenous hepcidin mo... |
| 21.10.2021 | Silence Therapeutics : Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication being assessed using endogenous hepcidin modulation - Form 6-K | Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication being assessed using endogenous hepcidin modulation
- SLN360 single-ascending dose study on-track for topline data in Q1'22 - independe... |
| 15.10.2021 | Silence Therapeutics : Press release, dated October 15, 2021, "Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading ... | Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market
Notice of General Meeting to be held on 1 November 2021
15 October 2021
LO... |
| 15.10.2021 | Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform | Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform
Hansoh will make a $16 million upfront cash payment and Silence has the potential to receive up to $1.3 billion ... |
| 15.10.2021 | Silence Therapeutics : Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market | Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market
Notice of General Meeting to be held on 1 November 2021
15 October 2021
LO... |
| 07.10.2021 | Silence Therapeutics to Host R&D Day on October 21, 2021 | Silence Therapeutics to Host R&D Day on October 21, 2021
7 October 2021
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfer... |
| 12.08.2021 | Silence Therapeutics Reports Half-Year 2021 Results | Silence Therapeutics Reports Half-Year 2021 Results Full enrollment achieved for four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of lipoprotein(a)Silence to host R&D Day in New York City on Octo... |
| 12.08.2021 | Silence Therapeutics : Full enrollment achieved for four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of lipoprotein(a) (Form 6-K) | Full enrollment achieved for four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of lipoprotein(a) - Silence to host R&D Day in New York City on October 21, 2021 August 12, 2021
LONDON, Silence Ther... |
| 25.05.2021 | Silence Therapeutics : Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration (Form 6-K) | Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration
- Companies on-track to initiate work on five targets within the first three years of the collaboration
25 Ma... |
| 25.05.2021 | SILENCE THERAPEUTICS PLC
Silence Therapeutics : Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration (Form 6-K) | Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration
- Companies on-track to initiate work on five targets within the first three years of the collaboration
25 Ma... |
| 25.05.2021 | ASTRAZENECA PLC
Silence Therapeutics plc Receives Remaining $40 million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration | Silence Therapeutics plc announced receipt of the remaining $40.0 million from AstraZeneca, due as part of AstraZenecas $80.0 million cash and equity investment for the siRNA collaboration announced in March 2020. The $40.0 million is incl... |
| 25.05.2021 | Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration | Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration Companies on-track to initiate work on five targets within the first three years of the collaboration
25 May ... |
| 19.05.2021 | Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers | Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers Data showed SLN124, an siRNA which targets TMPRSS6, was safe and effective in reducing plasma iron levels and had a long duration of acti... |
| 19.05.2021 | SILENCE THERAPEUTICS PLC
Silence Therapeutics : Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers (Form 6-K) | Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers
- Data showed SLN124, an siRNA which targets TMPRSS6, was safe and effective in reducing plasma iron levels and had a long duration of ac... |
| 04.05.2021 | Silence Therapeutics : SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse... | research paper
SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of b-thalassaemia
Jim Vadolas,1,2 Garrett... |
| 04.05.2021 | Silence Therapeutics Launches New Video Game to Support International Thalassemia Day and Raise Disease Awareness | Silence Therapeutics Launches New Video Game to Support International Thalassemia Day and Raise Disease Awareness
Play the free online game and share your score on social #BloodRunBeta
Silence partners with Thalassaemia International Federa... |
| 15.04.2021 | Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease | Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease
–High Lipoprotein(a) is a genetically determined card... |
| 30.03.2021 | SILENCE THERAPEUTICS PLC
Silence Therapeutics : Reports Full-year 2020 Results | Silence Therapeutics Reports Full-year 2020 Results
Advancing clinical programmes; On-track for three phase 1 data readouts in 2021
30 March 2021
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the C... |
| 04.03.2021 | Silence Therapeutics to Present at the Barclays Global Healthcare Conference | Silence Therapeutics to Present at the Barclays Global Healthcare Conference
4 March 2021
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel ... |
| 26.02.2021 | Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases | Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases Silence to receive $2 million research milestone payment Silence is also eligible to receive... |
| 18.02.2021 | Silence Therapeutics to Present at the 2021 SVB Leerink Global Healthcare Conference | Silence Therapeutics to Present at the 2021 SVB Leerink Global Healthcare Conference
18 February 2021
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delive... |
| 18.02.2008 | Quark Pharma: Not quite such a chameleon, after all | Last June, I posted about the long and winding history of Fremont, Calif.-based Quark Pharmaceuticals, a biotech developing drugs based on a new gene-silencing technology called RNA interference, or RNAi. At the time, I labeled the company ... |
| 28.01.2008 | RNA-drug developer Quark aims for $30M after failed IPO | Fremont, Calif.-based Quark Pharmaceuticals, a biotech developing drugs based on a new technology called RNA interference, hopes to raise $30 million in an eighth funding round, VentureWire reports. Last year, Quark sought $80.5 million in ... |
| 12.07.2007 | Roundup: Biogenerics bill in limbo, clashing data on health IT benefits, the RNAi boom, and more | House-Senate confrontation set over biogenerics — Late last month, a key group of senators reached agreement on legislative provisions that would authorize copycat versions of biotech drugs, which are typically complex proteins manufactured... |
| 09.07.2007 | How Big a Deal is Roche and Alnylam’s Big Deal? | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
The news wires are buzzing with today’s announcement of a deal between Alnylam and Roche that will give Roche nonexclusive access to Alnylam’s technology for developing RNAi-b... |
| 06.06.2007 | Biotech chameleons: Quark Pharma aims for $81M IPO | (UPDATED: See below.)
For some reason, biotechnology is rife with chameleons — companies that suddenly and radically alter their scientific strategy, disease focus or business model, sometimes to recover from a major failure, and sometimes ... |
